Skip to main content

Table 1 Demographic characteristics and OAB symptoms before treatment among studied patients in both groups

From: Overactive bladder symptoms recurrence after sudden versus gradual weaning of Solifenacin

Demographic characteristics Treatment protocol P value
Group I (sudden stopping)
N = 30
Group II (gradual weaning)
N = 30
Age; (years)
 Mean ± SD 48.10 ± 21.7 40.63 ± 14.04 0.119a
 95% CI1 for Mean
  Lower bound 39.98 35.39
  Upper bound 56.22 45.87
 Range (Max–Min) 67.00 (77–22) 46.00 (64–18)
Gender; n (%)
 Male; n = 21 10 (47.6) 11 (52.4) 0.500b
 Female; n = 39 20 (51.3) 19 (48.7)
OABSS; (before treatment)
 Mean ± SD 8.60 ± 1.8 8.13 ± 1.8 0.320a
 95% CI1 for Mean
  Lower bound 7.93 7.48
  Upper bound 9.26 8.79
 Range (Max–Min) 5.00 (11–6) 5.00 (11–6)
  1. 195% Confidence interval of mean
  2. aP value > 0.05 is considered non-significant by (independent sample t test)
  3. bP value > 0.05 is considered non-significant by (Chi-square test)